• SPX
  • $5,967.64
  • 0.32 %
  • $18.93
  • DJI
  • $44,163.22
  • 0.67 %
  • $292.87
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,259.86
  • 1.36 %
  • $110.59
  • IXIC
  • $18,997.85
  • 0.13 %
  • $25.43
Adaptimmune Therapeutics plc (ADAP) Stock Price, News & Analysis

Adaptimmune Therapeutics plc (ADAP) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.61

-$0.02

(-3.73%)

Day's range
$0.61
Day's range
$0.64
50-day range
$0.571
Day's range
$1.12
  • Country: GB
  • ISIN: US00653A1079
52 wk range
$0.42
Day's range
$2.05
  • CEO: Mr. Adrian G. Rawcliffe
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.36
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (ADAP)
  • Company Adaptimmune Therapeutics plc
  • Price $0.61
  • Changes Percentage (-3.73%)
  • Change -$0.02
  • Day Low $0.61
  • Day High $0.64
  • Year High $2.05

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $3.00
  • High Stock Price Target $4.00
  • Low Stock Price Target $1.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.73
  • Trailing P/E Ratio -1.4
  • Forward P/E Ratio -1.4
  • P/E Growth -1.4
  • Net Income $-113,871,000

Income Statement

Quarterly

Annual

Latest News of ADAP

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Adaptimmune Therapeutics plc Frequently Asked Questions

  • What were the earnings of ADAP in the last quarter?

    In the last quarter Adaptimmune Therapeutics plc earnings were on Monday, August, 12th. The Adaptimmune Therapeutics plc maker reported $0.24 EPS for the quarter, beating analysts' consensus estimates of -$0.07 by $0.31.

  • What is the Adaptimmune Therapeutics plc stock price today?

    Today's price of Adaptimmune Therapeutics plc is $0.61 — it has decreased by -3.73% in the past 24 hours. Watch Adaptimmune Therapeutics plc stock price performance more closely on the chart.

  • Does Adaptimmune Therapeutics plc release reports?

    Yes, you can track Adaptimmune Therapeutics plc's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Adaptimmune Therapeutics plc stock forecast?

    Watch the Adaptimmune Therapeutics plc chart and read a more detailed Adaptimmune Therapeutics plc stock forecast to see what analysts suggest you do with its shares.

  • What is Adaptimmune Therapeutics plc stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Adaptimmune Therapeutics plc stock ticker.

  • How to buy Adaptimmune Therapeutics plc stocks?

    Like other stocks, ADAP shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Adaptimmune Therapeutics plc's EBITDA?

    Adaptimmune Therapeutics plc measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Adaptimmune Therapeutics plc’s financial statements.

  • What is the Adaptimmune Therapeutics plc's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -1.8890031685, which equates to approximately -188.90%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Adaptimmune Therapeutics plc stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Adaptimmune Therapeutics plc's financials relevant news, and technical analysis. Adaptimmune Therapeutics plc's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Adaptimmune Therapeutics plc stock currently indicates a “sell” signal. For more insights, review Adaptimmune Therapeutics plc’s technical analysis.

  • A revenue figure for Adaptimmune Therapeutics plc for its last quarter?

    Adaptimmune Therapeutics plc published it's last quarterly revenues at $40.90 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.